Biotechnology company developing anti-LAP monoclonal antibodies that target the latent TGF-beta complex and modulate regulatory T-cell-mediated immune suppression
Biotechnology company developing anti-LAP monoclonal antibodies that target the latent TGF-beta complex and modulate regulatory T-cell-mediated immune suppression. Its immuno-oncology platform was aimed at treating cancer, with research also spanning fibrosis and autoimmune diseases. Tilos was acquired by Merck in 2019.